Sarepta Therapeutics Inc (SRPT)

36.26
NASDAQ : Health Care
Prev Close 34.72
Day Low/High 35.20 / 39.34
52 Wk Low/High 13.70 / 63.73
Avg Volume 2.21M
Exchange NASDAQ
Shares Outstanding 54.81M
Market Cap 1.90B
EPS -5.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal

Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal

The timing of these two departures could be coincidental and mean nothing, or they might signal Sanofi's interest in acquiring Sarepta.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

5 Earnings Short-Squeeze Plays: Twitter, Sarepta Therapeutics Included

5 Earnings Short-Squeeze Plays: Twitter, Sarepta Therapeutics Included

These heavily shorted stocks could get squeezed sharply higher if they report positive earnings this week.

Sarepta Pops on Bullish Sentiment Around Duchenne Therapy, PDL Up on Merck Deal: Biotech Movers

Sarepta Pops on Bullish Sentiment Around Duchenne Therapy, PDL Up on Merck Deal: Biotech Movers

Sarepta Therapeutics, Paratek Pharmaceuticals and PDL BioPharma were among the biotech stock movers in premarket trading on Monday.

It's Tough to Figure Out Where to Jump In

It's Tough to Figure Out Where to Jump In

If you aren't positioned long already, you are struggling with what to do here.

My Game Plan Is to Not Trust That Upside

My Game Plan Is to Not Trust That Upside

There has been enough technical damage done lately.

Shark Bites: You Don't Want to Play the Gambler Today

Shark Bites: You Don't Want to Play the Gambler Today

This is one of those days when it may pay to walk away.

Biotech Movers: Sarepta, Bellicum, Novavax

Biotech Movers: Sarepta, Bellicum, Novavax

Sarepta Therapeutics, Bellicum Pharmaceuticals and Novavax were among the biotech stock movers in premarket trading on Wednesday.

Market Is Home on the Range Again

Market Is Home on the Range Again

Emotion of yesterday's collapse is pretty much gone.

Shark Bites: Market Needs a Bounce in Its Step

Shark Bites: Market Needs a Bounce in Its Step

Biotechnology continues to be a bright spot.

Watching Financials and Biotech in This Tepid Market

Watching Financials and Biotech in This Tepid Market

Keep an eye on the pattern of morning weakness and afternoon strength.

Market Action Is Boring but Necessary

Market Action Is Boring but Necessary

After yesterday's surprise pullback, this is the sort of consolidation we need.

Market Taking a Break, but Probably Not for Long

Market Taking a Break, but Probably Not for Long

Today is more about stock picking.

Biotech Premarket Movers: Aurinia, Puma, PTC, Juno

Biotech Premarket Movers: Aurinia, Puma, PTC, Juno

Aurinia Pharmaceuticals, Puma Biotechnology, PTC Therapeutics and Juno Therapeutics were among the biotech stock movers in premarket trading on Thursday.

Notable Wednesday Option Activity: SRPT, PTCT, CBI

Notable Wednesday Option Activity: SRPT, PTCT, CBI

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sarepta Therapeutics Inc , where a total of 14,285 contracts have traded so far, representing approximately 1.4 million underlying shares. That amounts to about 60.3% of SRPT's average daily trading volume over the past month of 2.4 million shares.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, granted equity awards on February 28, 2017, that were previously approved by the Compensation Committee of...

Sarepta Therapeutics Announces Fourth Quarter And Full-Year 2016 Financial Results And Recent Corporate Developments

Sarepta Therapeutics Announces Fourth Quarter And Full-Year 2016 Financial Results And Recent Corporate Developments

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, today...

5 Stocks Set for Explosive Breakouts

5 Stocks Set for Explosive Breakouts

Here's how to rake in the profits off some potential big breakouts.

More Selling Pressure, But No Rush for the Exits

More Selling Pressure, But No Rush for the Exits

If you play strong defense, be prepared to change course very quickly.